Epidemiology

Epidemiology	
% Estimated prevalence of chronic	1.62 [1.29–2.03]
Hepatitis B infection (HBsAg+) ¹ Estimated prevalence of chronic HCV	0.57
infection ⁱⁱ (%) ⁱⁱⁱ	0.57
Estimated prevalence of chronic HCV	182 000
infection (N) ^{III}	
HCV prevalence among PWID [mean[95%	31.7 [22.6-41.6]
CI]]iv	
Hepatitis specific mortality rate per 100 000° (2013)	0.016
Liver cancer incidence (ASR ^{vi}) per 100 000 ^{vii}	5.2
(2012)	

Governance	
Presence of a focal point	Yes
Presence of STAG	FP*
Involvement of civil society	No
Units to implement national response	FP*
NSP (published or drafted)	Yes
Estimating cost to implement the NSP	Yes
Fund available for the NSP	No
Impact targets set	FP*
Service coverage targets set	FP*
Policies for stigma and discrimination	Yes
A system for Hepatitis prevention, testing, care and	
treatment services integrated at community, primary,	No
secondary and tertiary care levels has been defined	
Core hepatitis competencies of different cadres of	
health workers at different levels of the health system	No
been defined considering task shifting options	
Training and supervisory needs of health workers been	No
defined	
An investment case for an enhanced viral hepatitis	No
response been developed **	
A specific portion of National health budget had been	NI -
allocated to viral hepatitis prevention, care and treatment?	No
A set of essential viral hepatitis interventions been defined to be included in the national social / health	No
insurance package	NO
FP*: Future plans	
Surveillance	
National surveillance system for viral hepatitis	No
An inventory of existing data and sources of data on	No
viral hepatitis been made	

Testing policies	and guidelines		
Official guidance on which test to use for diagnosing		V	
HBV and/or HCV		Yes	
Official guidance on testing pregnant women for		No	
HBV		NO	
_	Official guidance on testing people who inject drugs		
(PWID) for HCV	Yes		
Official guidance or	2.2		
diagnosed with HB\	No		
referred for treatme			
National sources	Hepatitis B testing coverage of	Yes	
coverage targets been set for the	selected populations		
following	Hepatitis C testing coverage of	Yes	
indicators	selected populations	162	
	Policies for screening of		
	selected population groups at	No	
	increased risk		
Presence of	A policy for mandatory		
national policies	screening of all blood donations	Yes	
and guidelines	for Hepatitis B and C		
	for priority A policy for referral of all blood		
	interventions donors with positive screening		
	available and in results for Hepatitis B and C		
line with global confirmatory testing and case standards for the management			
	management Guidelines for diagnostic testing		
following	for Hepatitis B	No	
	Guidelines for diagnostic testing		
	for Hepatitis C	No	
	Percentage of blood donors		
Baseline values	screened for Hepatitis B and C	No	
been determined	Percentage of health facilities		
for the following	that implement the policy of	No	
global indicators	100% single use (or safety	140	
	engineered) injection devices		
Infrastructure fo			
Number of facilities that are Number of facilities that are			
able to offer ser	_		
testing for both I HBsAg) and HCV (-	
HCV)	RNA)	(i.e. ricv	
1101	THE		

Primary

level (i.e.

Secondary

Primary level

Secondary

3/7

Treatment policies and guidelines	
Tenofovir or Entecavir as the first line of treatment for HBV	No
Anti-nucleoside/nucleotide analogues are available for the treatment of hepatitis B	No
interferon-free (INF-free) direct-acting antiviral (DAA) are the regimens considered the first line of treatment for patients with chronic hepatitis C	No
Current treatment policy for people with chronic HCV	FP*
Current situation in terms of registration of Tenofovir or Entecavir specifically for HBV infection Current situation in terms of registration of	Yes**
medicines used in IFN-free DAA regimens for HCV infection	No
Tender (national or multinational) to launch price negotiations with pharmaceutical companies for HBV and/or HCV treatment	No
Hepatitis B treatment coverage	No
Hepatitis C treatment coverage	No
Guidelines for Hepatitis B treatment	No
Guidelines for Hepatitis C treatment	No
A strategy for achieving the best price for medicines and diagnostics been formulated and pursued	No
Treatment Estimates Estimate of the total number of people on antiviral	
treatment for HBV for the years 2013	NA
Estimate of the total number of people on antiviral treatment for HBV for the years 2015	NA
Estimate of the total number of people initiated on antiviral treatment for HCV for the years 2013	NA
Estimate of the total number of people initiated on antiviral treatment for HCV for the years 2015	NA
Estimate of the total number of people planned and budgeted for treatment of HBV infection in 2017	NA
Estimate of the total number of people planned and budgeted for treatment of HCV infection in 2017	NA
FP*: Policy not established, but plan is to establish one leads to stablish one leads to	-

Prevention		No
National	Hepatitis B vaccination of health workers	No
targets been set	Safe injections in health care settings	No
for the following indicators	Targets for number of needles- syringes distributed to PWID per year	No
_	A policy for Hepatitis B vaccination of health workers	Yes
Presence of national policies and guidelines for priority interventions	A policy to integrate Hepatitis B vaccination in services targeting people who inject drugs, men who have sex with men and sex workers	Yes
available and in line with global standards for the following	A policy for use of safe injections (or safety engineered devices) in health care settings to prevent transmission of blood borne infections	No
Baseline values	Coverage of hepatitis B vaccination of health workers,	No
been determined for the following global	For countries with significant PWID populations, coverage of needles-syringe distribution	No
indicators	For countries with significant PWID populations, HBV vaccination	No

HCV Elimination Targets			
	2017	2019	2020
Prevalence of Chronic HCV			
(%)	0.54%	0.50%	0.46%
Chronic HCV (N)	184	177	
	000	000	167 000
Diagnosed with HCV (%)	14.33%	18.2%	21.03%
Diagnosed with HCV (N)	26 300	32 300	35 200
HCV patients treated (%)	0.22%	1.80%	5.45%
HCV patients treated (N)	400	3 200	9 100
Number of new infections Sunday 8th of June 2025 02:28:4	19 PM 700	3 300	1 300